THE NEW YORK GLAUCOMA RESEARCH INS… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1995

Legal Domicile

Principal Officer

ROBERT RITCH MD

Phone

9173597390

Tax Period

2024-01-01 to 2024-12-31

THE NEW YORK GLAUCOMA RESEARCH INSTITUTE, founded in 1995, is a micro nonprofit in the Diseases & Disorders sector that reported $85K in total revenue in fiscal year 2024. Revenue surged 20% from the prior year, signaling strong growth momentum. The organization ran a surplus of $72K, a strong 84% operating margin.

Mission

TO PROMOTE RESEARCH INTO THE BASIC CAUSES OF GLAUCOMA, DEVELOP NEW TREATMENT MODALITIES FOR GLAUCOMA, AND DEVELOP PUBLIC EDUCATION INTO THE TREATMENT OF GLAUCOMA.

Program Service Accomplishments

Program 1

Expenses: $6,697

CONTINUED SCIENTIFIC RESEARCH INTO CAUSES AND TREATMENT OF GLAUCOMA AND THE ISSUANCE OF RELATED INFORMATION PUBLICATIONS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $12,760

Program Service Revenue $0

Investment Income $72,706

Other Revenue $0

TOTAL REVENUE $85,466

Expense Breakdown

Grants Paid $0

Salaries & Benefits $0

Fundraising Expenses $1,452

Program Expenses $6,697

Other Expenses $13,450

TOTAL EXPENSES $13,450

Year-over-Year Comparison

	2024	2023	Change
Revenue	$85,466	$71,016	+0.2%
Expenses	$13,450	$25,384	-0.5%
Net Income	$72,016	$45,632	+0.6%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MARSHALL J GLUCK	SECRETARY	1.00	Officer Director	$0	$0	$0
ROBERT RITCH MD	PRES. AND DI	10.00	Officer Director	$0	$0	$0
RIYO SAITO	TREASURER	1.00	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$85,466	$13,450	$1,236,452	$72,016
2023	$71,016	$25,384	$1,109,265	$45,632
2021	$29,192	$50,773	$1,205,090	$-21,581
2020	$108,779	$29,897	$1,068,179	$78,882
2019	$85,015	$112,541	$1,105,969	$-27,526
2018	$366,582	$92,173	$1,030,935	$274,409

THE NEW YORK GLAUCOMA RESEARCH INSTITUTE